{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:05:01Z","timestamp":1790449501814,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies","doi-asserted-by":"publisher","award":["Novartis Gene Therapies"],"award-info":[{"award-number":["Novartis Gene Therapies"]}],"id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10198-025-01806-2","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T06:28:12Z","timestamp":1750919292000},"page":"77-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-7495","authenticated-orcid":false,"given":"Ilaria","family":"Valentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Ghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Di Brino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele Maria","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"4","key":"1806_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb, S.J., Kissel, J.T.: Spinal muscular atrophy. Neurol. Clin. 33(4), 831\u2013846 (2015). https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004","journal-title":"Neurol. Clin."},{"key":"1806_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico, A., Mercuri, E., Tiziano, F.D., Bertini, E.: Spinal muscular atrophy. Orphanet J. Rare Dis. 6, 71 (2011). https:\/\/doi.org\/10.1186\/1750-1172-6-71","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"1806_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IE Verhaart","year":"2017","unstructured":"Verhaart, I.E., Robertson, A., Wilson, I.J., Aartsma-Rus, A., Cameron, S., Jones, C.C., Cook, S.F., Lochm\u00fcller, H.: Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2013a literature review. Orphanet J. Rare Dis. 12(1), 124 (2017). https:\/\/doi.org\/10.1186\/s13023-017-0671-8","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"1806_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00439-002-0828-x","volume":"110","author":"S Ogino","year":"2002","unstructured":"Ogino, S., Leonard, D.G.B., Rennert, H., Ewens, W.J., Wilson, R.B.: Genetic risk assessment in carrier testing for spinal muscular atrophy. Am. J. Med. Genet. 110(4), 301\u2013307 (2002). https:\/\/doi.org\/10.1007\/s00439-002-0828-x","journal-title":"Am. J. Med. Genet."},{"issue":"4","key":"1806_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill, K., K\u00f6lbel, H., Schwartz, O., Blaschek, A., Olgem\u00f6ller, B., Harms, E., Burggraf, S., R\u00f6schinger, W., Durner, J., Gl\u00e4ser, D., Nennstiel, U., Wirth, B., Schara, U., Jensen, B., Becker, M., Hohenfellner, K., M\u00fcller-Felber, W.: One year of newborn screening for SMA\u2013 results of a German pilot project. J. Neuromuscul. Dis. 6(4), 503\u2013515 (2019). https:\/\/doi.org\/10.3233\/JND-190428","journal-title":"J. Neuromuscul. Dis."},{"key":"1806_CR6","unstructured":"Orphanet Italia: Cerca una malattia rara. Atrofia muscolare spinale prossimale [Look for a rare disease. Proximal spinal muscular atrophy] [Website in Italian]. (2019). https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=IT%26data_id=633%26Disease_Disease_Search_diseaseGroup=Atrofia-Muscolare-Spinale-prossimale%26Disease_Disease_Search_diseaseType=Pat%26Malattia(e)\/%20gruppo%20di%20malattie=Atrofia-muscolare-spinale-prossimale%26title=Atrofia%20muscolare%20spinale%20prossimale%26search=Disease_Search_Simple Accessed 5 June 2024"},{"issue":"6","key":"1806_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.neuron.2005.12.001","volume":"48","author":"UR Monani","year":"2005","unstructured":"Monani, U.R.: Spinal muscular atrophy: A deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron. 48(6), 885\u2013895 (2005). https:\/\/doi.org\/10.1016\/j.neuron.2005.12.001","journal-title":"Neuron"},{"issue":"1","key":"1806_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling, D.C., Pechmann, A., Kirschner, J.: Advances in treatment of spinal muscular atrophy\u2013 new phenotypes, new challenges, new implications for care. J. Neuromuscul. Dis. 7(1), 1\u201313 (2020). https:\/\/doi.org\/10.3233\/JND-190424","journal-title":"J. Neuromuscul. Dis."},{"issue":"11","key":"1806_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1212\/WNL.0000000000201654","volume":"100","author":"G Coratti","year":"2023","unstructured":"Coratti, G., Ricci, M., Capasso, A., D\u2019Amico, A., Sansone, V., Bruno, C., et al.: Prevalence of spinal muscular atrophy in the era of disease-modifying therapies: An Italian nationwide survey. Neurology. 100(11), 522\u2013528 (2023). https:\/\/doi.org\/10.1212\/WNL.0000000000201654","journal-title":"Neurology"},{"issue":"7","key":"1806_CR10","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"H Chaytow","year":"2021","unstructured":"Chaytow, H., Faller, K.M.E., Huang, Y.T., Gillingwater, T.H.: Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell. Rep. Med. 2(7), 100346 (2021). https:\/\/doi.org\/10.1016\/j.xcrm.2021.100346","journal-title":"Cell. Rep. Med."},{"issue":"2","key":"1806_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy, S., Pickard, A.S., Kotha, K., Alfano, L.N., Lowes, L., Paul, G., Church, K., Lehman, K., Sproule, D.M., Dabbous, O., Maru, B., Berry, K., Arnold, W.D., Kissel, J.T., Mendell, J.R., Shell, R.: Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr. Pulmonol. 54(2), 179\u2013185 (2019). https:\/\/doi.org\/10.1002\/ppul.24203","journal-title":"Pediatr. Pulmonol."},{"issue":"18","key":"1806_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J.T., Nagendran, S., L\u2019Italien, J., Sproule, D.M., Wells, C., Cardenas, J.A., Heitzer, M.D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K.D., Burghes, A.H.M., Kaspar, B.K.: Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl. J. Med. 377(18), 1713\u20131722 (2017). https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl. J. Med."},{"issue":"19","key":"1806_CR13","doi-asserted-by":"publisher","first-page":"14873","DOI":"10.3390\/ijms241914873","volume":"24","author":"I Angilletta","year":"2023","unstructured":"Angilletta, I., Ferrante, R., Giansante, R., Lombardi, L., Babore, A., Dell\u2019Elice, A., Alessandrelli, E., Notarangelo, S., Ranaudo, M., Palmarini, C., De Laurenzi, V., Stuppia, L., Rossi, C.: Spinal muscular atrophy: An evolving scenario through new perspectives in diagnosis and advances in therapies. Int. J. Mol. Sci. 24(19), 14873 (2023). https:\/\/doi.org\/10.3390\/ijms241914873","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"1806_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras, B.T., Masson, R., Mazurkiewicz-Be\u0142dzi\u0144ska, M., Rose, K., Xiong, H., Zanoteli, E., Baranello, G., Bruno, C., Vlodavets, D., Wang, Y., El-Khairi, M., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R.S., Fontoura, P., Servais, L.: FIREFISH working group: Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl. J. Med. 385(5), 427\u2013435 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2102047","journal-title":"N Engl. J. Med."},{"issue":"7","key":"1806_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E., Darras, B.T., Chiriboga, C.A., Day, J.W., Campbell, C., Connolly, A.M., Iannaccone, S.T., Kirschner, J., Kuntz, N.L., Saito, K., Shieh, P.B., Tulinius, M., Mazzone, E.S., Montes, J., Bishop, K.M., Yang, Q., Foster, R., Gheuens, S., Bennett, C.F., Farwell, W., Schneider, E., De Vivo, D.C., Finkel, R.S., CHERISH Study Group: Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl. J. Med. 378(7), 625\u2013635 (2018). https:\/\/doi.org\/10.1056\/NEJMoa1710504","journal-title":"N Engl. J. Med."},{"issue":"1","key":"1806_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri, E., Deconinck, N., Mazzone, E.S., Nascimento, A., Oskoui, M., Saito, K., Vuillerot, C., Baranello, G., Boespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R.S., Staunton, H., Yeung, W.Y., Martin, C., Fontoura, P., Day, J.W., SUNFISH Study Group: Safety and efficacy of once daily Risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 21(1), 42\u201352 (2022). https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7","journal-title":"Lancet Neurol."},{"issue":"10","key":"1806_CR17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello, G., Darras, B.T., Day, J.W., Deconinck, N., Klein, A., Masson, R., Mercuri, E., Rose, K., El-Khairi, M., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R.S., Seabrook, T., Fontoura, P., Servais, L.: FIREFISH working group: Risdiplam in type 1 spinal muscular atrophy. N Engl. J. Med. 384(10), 915\u2013923 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2009965","journal-title":"N Engl. J. Med."},{"issue":"18","key":"1806_CR18","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., Chiriboga, C.A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A.M., Bishop, K., Zhong, Z.J., Gheuens, S., Bennett, C.F., Schneider, E., Farwell, W., De Vivo, D.C., ENDEAR Study Group: Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl. J. Med. 377(18), 1723\u20131732 (2017). https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl. J. Med."},{"issue":"4","key":"1806_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day, J.W., Finkel, R.S., Chiriboga, C.A., Connolly, A.M., Crawford, T.O., Darras, B.T., Iannaccone, S.T., Kuntz, N.L., Pe\u00f1a, L.D.M., Shieh, P.B., Smith, E.C., Kwon, J.M., Zaidman, C.M., Schultz, M., Feltner, D.E., Tauscher-Wisniewski, S., Ouyang, H., Chand, D.H., Sproule, D.M., Macek, T.A., Mendell, J.R.: Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20(4), 284\u2013293 (2021). https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6","journal-title":"Lancet Neurol."},{"issue":"10","key":"1806_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri, E., Muntoni, F., Baranello, G., Masson, R., Boespflug-Tanguy, O., Bruno, C., Corti, S., Daron, A., Deconinck, N., Servais, L., Straub, V., Ouyang, H., Chand, D., Tauscher-Wisniewski, S., Mendonca, N., Lavrov, A., STR1VE-EU study group: Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20(10), 832\u2013841 (2021). https:\/\/doi.org\/10.1016\/S1474-4422(21)00251-9","journal-title":"Lancet Neurol."},{"issue":"7","key":"1806_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss, K.A., Farrar, M.A., Muntoni, F., Saito, K., Mendell, J.R., Servais, L., McMillan, H.J., Finkel, R.S., Swoboda, K.J., Kwon, J.M., Zaidman, C.M., Chiriboga, C.A., Iannaccone, S.T., Krueger, J.M., Parsons, J.A., Shieh, P.B., Kavanagh, S., Tauscher-Wisniewski, S., McGill, B.E., Macek, T.A.: Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: The phase III SPR1NT trial. Nat. Med. 28(7), 1381\u20131389 (2022). https:\/\/doi.org\/10.1038\/s41591-022-01866-4","journal-title":"Nat. Med."},{"issue":"7","key":"1806_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss, K.A., Farrar, M.A., Muntoni, F., Saito, K., Mendell, J.R., Servais, L., McMillan, H.J., Finkel, R.S., Swoboda, K.J., Kwon, J.M., Zaidman, C.M., Chiriboga, C.A., Iannaccone, S.T., Krueger, J.M., Parsons, J.A., Shieh, P.B., Kavanagh, S., Tauscher-Wisniewski, S., McGill, B.E., Macek, T.A.: Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: The phase III SPR1NT trial. Nat. Med. 28(7), 1390\u20131397 (2022). https:\/\/doi.org\/10.1038\/s41591-022-01867-3","journal-title":"Nat. Med."},{"key":"1806_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","volume":"98","author":"LP Lowes","year":"2019","unstructured":"Lowes, L.P., Alfano, L.N., Arnold, W.D., Shell, R., Prior, T.W., McColly, M., Lehman, K.J., Church, K., Sproule, D.M., Nagendran, S., Menier, M., Feltner, D.E., Wells, C., Kissel, J.T., Al-Zaidy, S., Mendell, J.: Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr. Neurol. 98, 39\u201345 (2019). https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.05.005","journal-title":"Pediatr. Neurol."},{"issue":"1","key":"1806_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dmcn.14027","volume":"61","author":"T Gidaro","year":"2019","unstructured":"Gidaro, T., Servais, L.: Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps. Dev. Med. Child. Neurol. 61(1), 19\u201324 (2019). https:\/\/doi.org\/10.1111\/dmcn.14027","journal-title":"Dev. Med. Child. Neurol."},{"issue":"7","key":"1806_CR25","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","volume":"181","author":"M Pane","year":"2022","unstructured":"Pane, M., Donati, M.A., Cutrona, C., De Sanctis, R., Pirinu, M., Coratti, G., Ricci, M., Palermo, C., Berti, B., Leone, D., Ticci, C., Sacchini, M., Cerboneschi, M., Capasso, A., Cicala, G., Pera, M.C., Bravetti, C., Abiusi, E., Vaisfeld, A., Vento, G., Tiziano, F.D., Mercuri, E.: Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur. J. Pediatr. 181(7), 2821\u20132829 (2022). https:\/\/doi.org\/10.1007\/s00431-022-04470-3","journal-title":"Eur. J. Pediatr."},{"issue":"7","key":"1806_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jmg-2022-108873","volume":"60","author":"E Abiusi","year":"2023","unstructured":"Abiusi, E., Vaisfeld, A., Fiori, S., Novelli, A., Spartano, S., Faggiano, M.V., Giovanniello, T., Angeloni, A., Vento, G., Santoloci, R., Gigli, F., D\u2019Amico, A., Costa, S., Porzi, A., Panella, M., Ticci, C., Daniotti, M., Sacchini, M., Boschi, I., Dani, C., Agostiniani, R., Bertini, E., Lanzone, A., Lamarca, G., Genuardi, M., Pane, M., Donati, M.A., Mercuri, E., Tiziano, F.D., Italian, S.M.A.-N.B.S., Group: Experience of a 2-year spinal muscular atrophy NBS pilot study in italy: Towards specific guidelines and standard operating procedures for the molecular diagnosis. J. Med. Genet. 60(7), 697\u2013705 (2023). https:\/\/doi.org\/10.1136\/jmg-2022-108873","journal-title":"J. Med. Genet."},{"key":"1806_CR27","doi-asserted-by":"publisher","first-page":"1308296","DOI":"10.3389\/fneur.2024.1308296","volume":"15","author":"C Dosi","year":"2024","unstructured":"Dosi, C., Masson, R.: The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: A systematic literature review. Front. Neurol. 15, 1308296 (2024). https:\/\/doi.org\/10.3389\/fneur.2024.1308296","journal-title":"Front. Neurol."},{"issue":"3","key":"1806_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/ijns10030056","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper, K., Nalbant, G., Sutton, A., Harnan, S., Thokala, P., Chilcott, J., McNeill, A., Bessey, A.: Systematic review of presymptomatic treatment for spinal muscular atrophy. Int. J. Neonatal Screen. 10(3), 56 (2024). https:\/\/doi.org\/10.3390\/ijns10030056","journal-title":"Int. J. Neonatal Screen."},{"key":"1806_CR29","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","volume":"59","author":"M Pane","year":"2023","unstructured":"Pane, M., Berti, B., Capasso, A., Coratti, G., Varone, A., D\u2019Amico, A., Messina, S., Masson, R., Sansone, V.A., Donati, M.A., Agosto, C., Bruno, C., Ricci, F., Pini, A., Gagliardi, D., Filosto, M., Corti, S., Leone, D., Palermo, C., Onesimo, R., De Sanctis, R., Ricci, M., Bitetti, I., Sframeli, M., Dosi, C., Albamonte, E., Ticci, C., Brolatti, N., Bertini, E., Finkel, R., Mercuri, E.: ITASMAc group: Onasemnogene abeparvovec in spinal muscular atrophy: Predictors of efficacy and safety in Na\u00efve patients with spinal muscular atrophy and following switch from other therapies. EClinicalMedicine. 59, 101997 (2023). https:\/\/doi.org\/10.1016\/j.eclinm.2023.101997","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1806_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff, T., Botty, C., Beaudart, C., Servais, L., Hiligsmann, M.: Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J. Rare Dis. 16(1), 47 (2021). https:\/\/doi.org\/10.1186\/s13023-021-01695-7","journal-title":"Orphanet J. Rare Dis."},{"key":"1806_CR31","unstructured":"Italian Medicines Agency (AIFA): Valutazioni Economiche [Economic Evaluations] [Article in Italian]. AIFA. (2024). https:\/\/www.aifa.gov.it\/en\/valutazioni-economiche Accessed 5 December 2024"},{"key":"1806_CR32","unstructured":"Fiorentino, F., Urbinati, D.: First Italian guidelines for the economic evaluation of health technologies: How do they compare to. NICE Standards?? GIHTAD 14(5) (2021)"},{"key":"1806_CR33","doi-asserted-by":"crossref","unstructured":"Marcellusi, A., Bini, C., Casiraghi, J., D\u2019Ambrosio, F., Rotundo, M.A., Pallara, A., Mennini, F.S.: Cost of illness of spinal muscular atrophy (SMA) in Italy. Global & Regional Health Technology Assessment, 2019, 2284240319867662. (2019)","DOI":"10.1177\/2284240319867662"},{"issue":"1","key":"1806_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","volume":"16","author":"K Vill","year":"2021","unstructured":"Vill, K., Schwartz, O., Blaschek, A., Gl\u00e4ser, D., Nennstiel, U., Wirth, B., Burggraf, S., R\u00f6schinger, W., Becker, M., Czibere, L., Durner, J., Eggermann, K., Olgem\u00f6ller, B., Harms, E., Schara, U., K\u00f6lbel, H., M\u00fcller-Felber, W.: Newborn screening for spinal muscular atrophy in germany: Clinical results after 2 years. Orphanet J. Rare Dis. 16(1), 153 (2021). https:\/\/doi.org\/10.1186\/s13023-021-01783-8","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"1806_CR35","doi-asserted-by":"publisher","first-page":"19922","DOI":"10.1038\/s41598-021-99496-2","volume":"11","author":"F Boemer","year":"2021","unstructured":"Boemer, F., Caberg, J.-H., Beckers, P., Dideberg, V., di Fiore, S., Bours, V., Marie, S., Dewulf, J., Marcelis, L., Deconinck, N., Daron, A., Blasco-Perez, L., Tizzano, E., Hiligsmann, M., Lombet, J., Pereira, T., Lopez-Granados, L., Shalchian-Tehran, S., van Assche, V., Willems, A., Huybrechts, S., Mast, B., van Olden, R., Dangouloff, T., Servais, L.: Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium. Sci. Rep. 11(1), 19922 (2021). https:\/\/doi.org\/10.1038\/s41598-021-99496-2","journal-title":"Sci. Rep."},{"key":"1806_CR36","unstructured":"Italian National Statistics Institute (Istat): Life tables: (2023). http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_MORTALITA1=en (2023). Accessed 5 June 2024"},{"key":"1806_CR37","doi-asserted-by":"publisher","unstructured":"Finkel, R.S., Serjesen, T., Mercuri, E., ENMC SMA Workshop Study Group.: &: 218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19\u201321 February 2106. Neuromuscul. Disord. 27(6), 596\u2013605 (2017). https:\/\/doi.org\/10.1016\/j.nmd.2017.02.014","DOI":"10.1016\/j.nmd.2017.02.014"},{"key":"1806_CR38","doi-asserted-by":"publisher","unstructured":"Finkel, R.S., Mercuri, E., Meyer, O.H., Simonds, A.K., Schroth, M.K., Graham, R.J., Kirschner, J., Iannaccone, S.T., Crawford, T.O., Woods, S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E.S., Vitale, M., Snyder, B., Quijano-Roy, S., Bertini, E., Davis, R.H., Qian, Y., Sejersen, T.: SMA care group: Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul. Disord. 28(3), 197\u2013207 (2018). https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004","DOI":"10.1016\/j.nmd.2017.11.004"},{"issue":"2","key":"1806_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri, E., Finkel, R.S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E.S., Vitale, M., Snyder, B., Quijano-Roy, S., Bertini, E., Davis, R.H., Meyer, O.H., Simonds, A.K., Schroth, M.K., Graham, R.J., Kirschner, J., Iannaccone, S.T., Crawford, T.O., Woods, S., Qian, Y., Sejersen, T., SMA Care Group: Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul. Disord. 28(2), 103\u2013115 (2018). https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005","journal-title":"Neuromuscul. Disord"},{"key":"1806_CR40","doi-asserted-by":"publisher","unstructured":"Wang, C.H., Finkel, R.S., Bertini, E.S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T.O., Trela, A.: & Participants of the International Conference on SMA Standard of Care: Consensus statement for standard of care in spinal muscular atrophy. J. Child Neurol. 22(8), 1027\u20131049 (2007). https:\/\/doi.org\/10.1177\/088307380730578","DOI":"10.1177\/088307380730578"},{"issue":"1","key":"1806_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2009.10.028","volume":"46","author":"J van Loon","year":"2010","unstructured":"van Loon, J., Grutters, J.P., Wanders, R., Boersma, L., Dingemans, A.M., Bootsma, G., Geraedts, W., Pitz, C., Simons, J., Brans, B., Snoep, G., Hochstenbag, M., Lambin, P., De Ruysscher, D.: 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation. Eur. J. Cancer. 46(1), 110\u2013119 (2010). https:\/\/doi.org\/10.1016\/j.ejca.2009.10.028","journal-title":"Eur. J. Cancer"},{"key":"1806_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF03320660","volume":"11","author":"G Fattore","year":"2009","unstructured":"Fattore, G.: Proposta Di Linee Guida per La valutazione economica Degli interventi sanitari in Italia [Proposal of guidelines for the economic evaluation of health interventions in Italy] [Article in Italian]. Pharmacoeconomics Ital. Res. Articles. 11, 83\u201393 (2009). https:\/\/doi.org\/10.1007\/BF03320660","journal-title":"Pharmacoeconomics Ital. Res. Articles"},{"issue":"5","key":"1806_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1524-4733.2005.00045.x","volume":"8","author":"S Ramsey","year":"2005","unstructured":"Ramsey, S., Willke, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., Cook, J., Glick, H., Liljas, B., Petitti, D., Reed, S.: Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA task force report. Value Health. 8(5), 521\u2013533 (2005). https:\/\/doi.org\/10.1111\/j.1524-4733.2005.00045.x","journal-title":"Value Health"},{"issue":"3","key":"1806_CR44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho, M., Bernal, S., Al\u00edas, L., March, F., Vencesl\u00e1, A., Rodr\u00edguez-\u00c1lvarez, F.J., Aller, E., Fern\u00e1ndez, R.M., Borrego, S., Mill\u00e1n, J.M., Hern\u00e1ndez-Chico, C., Cusc\u00f3, I., Fuentes-Prior, P., Tizzano, E.F.: Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 28(3), 208\u2013215 (2018). https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003","journal-title":"Neuromuscul. Disord"},{"issue":"5","key":"1806_CR45","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara, R., Brazier, J.E.: Populating an economic model with health state utility values: Moving toward better practice. Value Health. 13(5), 509\u2013518 (2010). https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00700.x","journal-title":"Value Health"},{"key":"1806_CR46","unstructured":"Institute for Clinical and Economic Review: Spinraza\u00ae and Zolgensma\u00ae for Spinal Muscular Atrophy: Effectiveness and Value. Final Evidence Report. (2019). https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_052419.pdf Accessed 5 June 2024"},{"issue":"Suppl 3","key":"1806_CR47","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1016\/j.jval.2018.09.2008","volume":"21","author":"LS D\u2019Angiolella","year":"2018","unstructured":"D\u2019Angiolella, L.S., Belisari, A., Mantovani, L.G., Sansone, V., Vita, G., Pane, M.: PND41 - Healthcare costs of patients with spinal muscular atrophy. Value Health. 21(Suppl 3), S336 (2018)","journal-title":"Value Health"},{"issue":"Suppl 1","key":"1806_CR48","doi-asserted-by":"publisher","first-page":"104441","DOI":"10.1016\/j.nmd.2024.07.623","volume":"43","author":"BT Darras","year":"2024","unstructured":"Darras, B.T., Farrar, M., Mercuri, E., Strauss, K., Day, J., Chien, Y.-H., Masson, R., Bernardo, R., Alecu, I., Dodd, N., Mehl, L., Connolly, A.: 179P intravenous and intrathecal onasemnogene abeparvovec gene therapy in symptomatic and presymptomatic spinal muscular atrophy: Long-term follow-up study neuromuscul. Disord. 43(Suppl 1), 104441 (2024). https:\/\/doi.org\/10.1016\/j.nmd.2024.07.623","journal-title":"Disord"},{"issue":"11","key":"1806_CR49","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"C De Vivo","year":"2019","unstructured":"De Vivo, C., Bertini, E., Swoboda, K.J., Hwu, W.L., Crawford, T.O., Finkel, R.S., Kirschner, J., Kuntz, N.L., Parsons, J.A., Ryan, M.M., Butterfield, R.J., Topaloglu, H., Ben-Omran, T., Sansone, V.A., Jong, Y.J., Shu, F., Staropoli, J.F., Kerr, D., Sandrock, A.W., Stebbins, C., Petrillo, M., Braley, G., Johnson, K., Foster, R., Gheuens, S., Bhan, I., Reyna, S.P., Fradette, S., Farwell, W., NUTURE Study Group: Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul. Disord. 29(11), 842\u2013856 (2019). https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007","journal-title":"Neuromuscul. Disord"},{"key":"1806_CR50","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40261-024-01386-8","volume":"44","author":"G Ghetti","year":"2024","unstructured":"Ghetti, G., Mennini, F.S., Marcellusi, A., Bischof, M., Pistillo, G.M., Pane, M.: Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Italy. Clin. Drug Investig. 44, 687\u2013701 (2024). https:\/\/doi.org\/10.1007\/s40261-024-01386-8","journal-title":"Clin. Drug Investig"},{"key":"1806_CR51","unstructured":"Bini, C., Marcellusi, A., Ghetti, G., Pistillo, G.M., Pane, M., Mennini, F.S.: Newborn screening for spinal muscular atrophy in Italy: Economic and policy analyses. Poster presented at: ISPOR Italy-Rome Chapter National Conference; November 28\u201329, 2022; Rome, Italy"},{"issue":"3","key":"1806_CR52","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","volume":"62","author":"BT Darras","year":"2015","unstructured":"Darras, B.T.: Spinal muscular atrophies. Pediatr. Clin. North. Am. 62(3), 743\u2013766 (2015). https:\/\/doi.org\/10.1016\/j.pcl.2015.03.010","journal-title":"Clin. North. Am."},{"key":"1806_CR53","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman, R.I., Wijngaarde, C.A., Stam, M., Bartels, B., Otto, L.A.M., Lemmink, H.H., Schoenmakers, M.A.G.C., Cuppen, I., van den Berg, L.H., van der Pol, W.L.: Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur. J. Neurol. 25, 512\u2013518 (2018). https:\/\/doi.org\/10.1111\/ene.13534","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"1806_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","volume":"32","author":"V Diaby","year":"2014","unstructured":"Diaby, V., Adunlin, G., Montero, A.J.: Survival modeling for the Estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: A tutorial. Pharmacoeconomics. 32(2), 101\u2013108 (2014). https:\/\/doi.org\/10.1007\/s40273-013-0123-9","journal-title":"Pharmacoeconomics"},{"key":"1806_CR55","unstructured":"Agenzia Italiana del Farmaco (AIFA): Tabelle farmaci di classe A e H al 16\/05\/2022 [Class A and H drug tables as of 05\/16\/2022] [Website in Italian]. AIFA. (2022). https:\/\/www.aifa.gov.it\/-\/tabelle-farmaci-di-classe-a-e-h-al-16\/05\/2022 Accessed 5 June 2024"},{"key":"1806_CR56","unstructured":"Gazzetta Ufficiale della Repubblica Italiana: Ministero della Salute Decreto 18 ottobre 2012: Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Allegato 1 [Ministry of Health. Decree 18 October 2012. Remuneration for acute hospital care, rehabilitation and long-term post-acute hospital care and specialist outpatient care. Attachment 1] [Website in Italian]. Gazzetta Ufficiale della Repubblica Italiana. (2013). https:\/\/www.gazzettaufficiale.it\/eli\/id\/2013\/01\/28\/13A00528\/sg Accessed 5 June 2024"},{"key":"1806_CR57","unstructured":"Regione Lombardia La Giunta: Delibera N\u00b0 IX \/ 2946 Seduta del 25\/01\/2012. Oggetto: Precisazioni in ordine alla dgr n. IX\/2633 del 06 dicembre 2011 determinazioni in ordine alla gestione del servizio socio sanitario regionale per l\u2019esercizio 2012 [Resolution No. IX \/ 2946 Session of 01\/25\/2012. Subject: Clarifications regarding the legislative decree n. IX \/ 2633 of 06 December 2011 determinations regarding the management of the regional social and health service for the 2012 financial year] [Website in Italian]. Regione Lombardia La Giunta. (2012). https:\/\/www.asst-pavia.it\/sites\/default\/files\/documenti\/DGR_2946_25gen12TARIFFE.pdf Accessed 5 June 2024"},{"key":"1806_CR58","unstructured":"Istituto Nazionale di Statistica: (Istat): National life tables: Italy 2018\u20132020. (2022). https:\/\/demo.istat.it\/index.php Accessed 5 June 2024"},{"issue":"15","key":"1806_CR59","doi-asserted-by":"publisher","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","volume":"94","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde, C.A., Stam, M., Otto, L.A.M., van Eijk, R.P.A., Cuppen, I., Veldhoen, E.S., van den Berg, L.H., Wadman, R.I., van der Pol, W.L.: Population-based analysis of survival in spinal muscular atrophy. Neurology. 94(15), e1634\u2013e1644 (2020). https:\/\/doi.org\/10.1212\/WNL.0000000000009248","journal-title":"Neurology"},{"issue":"6","key":"1806_CR60","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb, S.J., Coffey, C.S., Yankey, J.W., Krosschell, K., Arnold, W.D., Rutkove, S.B., Swoboda, K.J., Reyna, S.P., Sakonju, A., Darras, B.T., Shell, R., Kuntz, N., Castro, D., Parsons, J., Connolly, A.M., Chiriboga, C.A., McDonald, C., Burnette, W.B., Werner, K., Thangarajh, M., Shieh, P.B., Finanger, E., Cudkowicz, M.E., McGovern, M.M., McNeil, D.E., Finkel, R., Iannaccone, S.I., Kaye, E., Kingsley, A., Renusch, S.R., McGovern, V.L., Wang, X., Zaworski, P.G., Prior, T.W., Burghes, A.H.M., Bartlett, A., Kissel, J.T.: & neuronext clinical trial network on behalf of the NN101 SMA biomarker investigators: Natural history of infantile-onset spinal muscular atrophy. Ann. Neurol. 82(6), 883\u2013891 (2017). https:\/\/doi.org\/10.1002\/ana.25101","journal-title":"Ann. Neurol."},{"issue":"5","key":"1806_CR61","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti, C., Ottonello, G., Chiarini Testa, M.B., Mastella, C., Rav\u00e0, L., Bignamini, E., Veljkovic, A., Cutrera, R.: Survival of patients with spinal muscular atrophy type 1. Pediatrics. 131(5), e1509\u2013e1514 (2013). https:\/\/doi.org\/10.1542\/peds.2012-2278","journal-title":"Pediatrics"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01806-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-025-01806-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01806-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:04:50Z","timestamp":1771862690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-025-01806-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1007\/s10198-025-01806-2","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As no new studies with human participants were included in this analysis, Institutional Review Board approval was not required, patient consent to participate was not necessary, and the Declaration of Helsinki 1964 does not apply.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Gianni Ghetti is an employee of AdRes HEOR s.r.l., which has received project funding from Novartis Gene Therapies, Inc.\/Novartis Pharma AG. Marika Pane was supported by Novartis for this study. Matthias Bischof is an employee of Novartis Pharma AG, Basel, Switzerland, and owns Novartis stock or other equities. Gabriele Maria Pistillo is an employee of Novartis Pharma AG, Basel, Switzerland, and owns Novartis stock or other equities. Filippo Rumi, Ilaria Valentini, Eugenio Di Brino, and Michele Basile do not have any conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}